

Special Issue

Pathogenesis and Treatment of Preeclampsia

Message from the Guest Editors

Preeclampsia is a pregnancy-specific hypertensive disorder with multisystem involvement. It is one of the “great obstetrical syndromes” with multiple etiologic factors that converge to an angiogenic imbalance, such as endothelial dysfunction. Preeclampsia complicates 5–8% of pregnancies worldwide and is one of the main causes of maternal and perinatal morbidity and mortality. Despite the increase in knowledge of its pathogenesis, there is no specific cure for this disease, other than delivery. Therefore, there is an urgent need for therapeutic strategies to prolong pregnancy in the case of early-onset forms and to prevent/reduce maternal-fetal-neonatal complications. This Special Issue aims to collate research that explores all potential therapies for the prevention and treatment of preeclampsia, in the light of new etiopathogenetic evidence.

Guest Editors

Dr. Patrizia Vergani

Department of Obstetrics and Gynecology, University of Milano-Bicocca, 20900 Monza, Italy

Dr. Valentina Giardini

Department of Obstetrics and Gynecology, IRCCS San Gerardo dei Tintori Foundation, University of Milano-Bicocca, 20900 Monza, Italy

Deadline for manuscript submissions

closed (31 August 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/184439

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).